GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (STU:HQE1) » Definitions » Stock Based Compensation

CytoSorbents (STU:HQE1) Stock Based Compensation : €3.27 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is CytoSorbents Stock Based Compensation?

CytoSorbents's Stock Based Compensation for the three months ended in Mar. 2024 was €0.85 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €3.27 Mil.


CytoSorbents Stock Based Compensation Historical Data

The historical data trend for CytoSorbents's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Stock Based Compensation Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 3.87 5.49 3.59 3.39

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.19 1.27 0.96 0.85

CytoSorbents Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.27 Mil.


CytoSorbents Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (STU:HQE1) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

CytoSorbents (STU:HQE1) Headlines

No Headlines